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Abstract
Background: The study of breast cancer metastasis depends on the use of established breast cancer cell lines that
do not accurately represent the heterogeneity and complexity of human breast tumors. A tumor model was
developed using primary breast tumor-initiating cells isolated from patient core biopsies that would more
accurately reflect human breast cancer metastasis.
Methods: Tumorspheres were isolated under serum-free culture conditions from core biopsies collected from five
patients with clinical diagnosis of invasive ductal carcinoma (IDC). Isolated tumorspheres were transplanted into the
mammary fat pad of NUDE mice to establish tumorigenicity in vivo. Tumors and metastatic lesions were analyzed
by hematoxylin and eosin (H+E) staining and immunohistochemistry (IHC).
Results: Tumorspheres were successfully isolated from all patient core biopsies, independent of the estrogen
receptor a (ERa)/progesterone receptor (PR)/Her2/neu status or tumor grade. Each tumorsphere was estimated to
contain 50-100 cells. Transplantation of 50 tumorspheres (1-5 × 10
3 cells) in combination with Matrigel into the
mammary fat pad of NUDE mice resulted in small, palpable tumors that were sustained up to 12 months post-
injection. Tumors were serially transplanted three times by re-isolation of tumorspheres from the tumors and
injection into the mammary fat pad of NUDE mice. At 3 months post-injection, micrometastases to the lung, liver,
kidneys, brain and femur were detected by measuring content of human chromosome 17. Visible macrometastases
were detected in the lung, liver and kidneys by 6 months post-injection. Primary tumors variably expressed
cytokeratins, Her2/neu, cytoplasmic E-cadherin, nuclear b catenin and fibronectin but were negative for ERa and
vimentin. In lung and liver metastases, variable redistribution of E-cadherin and b catenin to the membrane of
tumor cells was observed. ERa was re-expressed in lung metastatic cells in two of five samples.
Conclusions: Tumorspheres isolated under defined culture conditions from patient core biopsies were tumorigenic
when transplanted into the mammary fat pad of NUDE mice, and metastasized to multiple mouse organs.
Micrometastases in mouse organs demonstrated a dormancy period prior to outgrowth of macrometastases. The
development of macrometastases with organ-specific phenotypic distinctions provides a superior model for the
investigation of organ-specific effects on metastatic cancer cell survival and growth.
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Breast cancer is a heterogeneous disease that remains
the second leading cause of death among women. Meta-
static disease increases mortality from breast cancer by
70% and is the leading cause of death in breast cancer
patients independent of the manageability of the pri-
mary disease. Although generally correlated with later
stages in disease progression, there is mounting evidence
suggesting the metastatic process may initiate earlier in
breast cancer development. Therefore, tumor volume at
diagnosis may not accurately predict the presence of
metastatic disease or the initiation of the metastatic pro-
cess. Metastatic disease can remain dormant and unde-
tectable for months to years, resulting in recurrence at
the primary site and/or the development of metastatic
lesions at distant sites [1,2]. Efficacious treatments for
metastatic disease depends on development of preclini-
cal tumor models that better predict patient response,
increase understanding of the metastatic process, and
enable the identification of biomarkers for earlier and
more accurate detection of metastasis.
The study of breast cancer has depended heavily upon
the use of established breast cancer cell lines, whose origin
is often from pleural effusions or metastatic lesions.
Although significant advancements have been made possi-
ble through the use of established cell lines, further pro-
gress depends on the development of tumor models that
more accurately represent the heterogeneous nature of
human breast tumors. Hetero-transplantation of primary
tumor biopsies from patients into immune-deficient mice
has many advantages over standard xenografts from can-
cer cell lines. The hetero-transplant tumors can be directly
compared to the original patient tumor biopsies, and to
annotated information on patient features, family history,
patient outcome etc. A study of breast cancer hetero-
transplants revealed that patients whose breast cancer
biopsies grew as tumors in mice predicted a worse prog-
nosis compared to biopsies that did not grow tumors [3].
Unfortunately, only a very small percentage of human
breast tumor tissue directly transplanted into immune-
deficient mice results in tumor formation [3-5]. The iden-
tification of breast cancer stem cells (bCSCs) in breast
tumors shifted the previously held hypothesis that all cells
within a tumor retained the ability to recapitulate the
tumor [6]. BCSCs, present in tumors at very low frequency
[7], have been implicated in breast tumor progression [8],
metastasis [9] and recurrence [10]. The relative quiescence
of bCSCs [11] and the elevated expression of ABC trans-
porter family of proteins [12] may contribute to bCSCs
evasion of traditional chemotherapy and radiotherapy.
Furthermore, recent data has shown that chemotherapeu-
tics [13,14] and radiation [15] may enrich for bCSCs, pos-
sibly increasing risk of recurrence.
A subset of cells isolated from primary breast tumors
are termed breast tumor-initiating cells (bTICs) for the
ability to form tumors upon injection of low numbers
into the mammary fat pad of immune-deficient mice
[7]. BTICs consist of a heterogeneous population of
cells that include a small percentage of bCSCs as well as
a range of less to more differentiated progenitor cells.
BTICs have been shown to exist in vitro as tumor-
spheres upon selection under non-adherent, serum-free
conditions [16]. Recently, it has been suggested that
bTICs are the cells within tumors with metastatic
potential and the ability to “seed” in distant organs [17].
Therefore, the challenges in targeting bTICs likely
extend from the primary site of tumor formation to dis-
tant metastatic sites as well. Given the evidence that
supports bTICs as the cells with metastatic potential
and the source of breast cancer recurrence, tumor mod-
els that employ bTICs isolated directly from patient
biopsies may provide a more reliable means for study of
the metastatic process and tumor recurrence.
Disseminated breast cancer cells may be present at
distant sites at the time of primary diagnosis of breast
cancer in patients that exhibit no outward signs of clini-
cal metastasis [18,19]. Although current models of
breast cancer metastasis have provided great insight into
some of the contributing molecular mechanisms, these
models have failed to recapitulate the dormancy period
observed clinically. Exit from the dormant state is neces-
sary for the development of macro-metastatic lesions in
distant organs, yet the mechanisms involved are poorly
understood [17,20,21]. The purpose of this study was to
develop a novel and reproducible breast cancer model
using bTICs isolated as tumorspheres from patient biop-
sies for the investigation of the metastatic process.
Methods
Isolation of tumorspheres
Tumorspheres were isolated using a procedure pre-
viously described by this laboratory [22] and derived
from Dontu et al. [23]. Briefly, breast cancer needle
biopsies from primary patient tumors were obtained
during the routine care of patients with consent and
Tulane IRB approved protocol (IRB # 07-00042). Biop-
sies were performed using a 14 gauge spring-loaded gun
yielding about 15-20 mg of tissue in each core sample.
3-5 core biopsy samples (2 cm in length) were obtained
from each consenting patient. Tissue samples were
placed on ice in 1× Hanks buffered saline solution
(HBSS) until processing. Tissues were mechanically dis-
sociated using sterile scalpels into ~2 mm
2 pieces fol-
lowed by enzymatic dissociation in collagenase (300 U/
ml) and hyaluronidase (100 U/ml) (Stem Cell Technolo-
gies) diluted in complete DMEM/F12 media (see below)
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Page 2 of 16for 3-5 h at 37 deg with agitation every 20-25 min. The
resultant cell suspension was sequentially filtered
through a 100 μma n d4 0μm pore filter (Fisher) and
centrifuged at 300 × g for 10 min. The cell pellet was
resuspended in complete DMEM/F12 media (see below)
a n dc u l t u r e di na1 0 0m m
2 ultra low attachment plate
(Corning).
Cell culture
Cells isolated from tissue samples were incubated in
DMEM/F12 media containing 1× B-27 serum-free sup-
plement (Invitrogen), 0.4% bovine serum albumin (BSA)
(Sigma), 20 ng/ml epidermal growth factor (EGF)
(Sigma), 10 ng/ml basic fibroblast growth factor (bFGF)
(Sigma), 4 ug/ml insulin, human recombinant (Sigma),
and Penicillin (100 U/ml)/Streptomycin (100 U/ml).
Cells were cultured for 10-14 days to allow tumorsphere
formation. Cells were pelleted every 3 days by centrifu-
gation at 300 × g for 10 min. and resuspended in com-
plete DMEM/F12 media supplemented with fresh EGF
and bFGF.
Animal experiments
Immunodeficient Nu/Nu female mice were purchased
from Charles River Laboratories (US). Mice were 25-35
days of age at time of tumorsphere injection. All experi-
ments were performed under approved Tulane IACUC
protocol (IACUC # 2941 R-D). Tumorspheres were
washed twice with cold 1× PBS then resuspended to
yield 1000-5000 cells/100 μl in cold 1× PBS. Immedi-
ately before injection, cells were combined with 100 μl
BD Matrigel Basement Membrane matrix (BD Bios-
ciences). Mice were anesthetized by i.p. injection of 0.3
ml of a ketamine solution. Cell suspensions were
injected bilaterally into the third mammary fat pad.
Mice were monitored weekly for tumor formation by
caliper measurement, and for body weight for up to 12
months. If no weight loss or other indications of declin-
ing health was observed, animals were euthanized 12
months post injection to permit detection of metastases,
and to harvest fresh tumor for serial transplantation.
DNA isolation and PCR analysis of tumors and mouse
tissues
For DNA analysis, tissues were collected using auto-
claved dissection tools and placed immediately into ster-
ile polypropylene 15 ml conical tubes at a ratio of 5 ml
RNAlater (Qiagen) per 200 mg of tissue. Tissues were
either processed immediately or stored at -20 deg. Tis-
sues were homogenized using an electric homogenizer
(TH-01, Omni TH, tissue homogenizer) at 25,000 rpm
for 2 min. with autoclaved Omni homogenizer tips (8
mm diameter, 110 mm length, processing range of 0.25-
30 ml) (Omni International). Cell lysis and all
subsequent steps for the isolation of DNA and RNA
from the homogenized tissues were carried out as
described in the instruction manual for the Allprep
DNA/RNA isolation kit (Qiagen). Briefly, homogenized
tissues were loaded onto a spin column that bound
DNA and eluted the fraction containing RNA following
centrifugation at room temperature. The eluent was
combined with 70% ethanol and added to a 2nd spin
column. Following several washes, RNA was eluted and
quantified. DNA was also eluted from the 1st spin col-
umn and quantified. Human cells were detected in
mouse tissues using PCR for detection of an alpha-satel-
lite DNA sequence of the centromere region of human
chromosome 17 as previously described by Becker et al
[24].
Hematoxylin and eosin staining
Tissues were collected and placed in 10% neutral buf-
fered formalin (Fisher) equal to 20 times the tissue
volume. Tissues were incubated overnight at room tem-
perature and then processed by standard formalin fixa-
tion, paraffin embedding and sectioning by The Center
f o rG e n eT h e r a p yH i s t o l o g yC o r eF a c i l i t y ,T u l a n eU n i -
versity. 5 μm sections were deparaffinized and rehy-
drated in a graded series of ethanol solutions, from
100% to 75%. Sections were then stained using Gill’s
Hematoxylin and Eosin (Poly Scientific) followed by
dehydration through a graded series of ethanol solutions
from 75% to 100%. Image J software was used to quan-
tify the metastatic burden within the tissues analyzed.
To calculate the metastatic burden present in the mouse
organs, the number of pixels within the defined area of
the metastatic lesion/s was determined (x pixels). Next,
the total number of pixels within the field of view was
determined (y pixels). The metastatic burden within the
field of view was then calculated by dividing the pixels
present in the metastatic lesion/s, by the total pixels
comprising the field of view then multiplying by 100 [(x
pixels/y pixels)*100] resulting in a percent metastatic
burden. The average of 5 fields of view (100× magnifica-
tion) was used to determine metastatic burden present
in each organ analyzed.
TUNEL (TdT-mediated dUTP nick end labeling)
For TUNEL, 5 μm sections were rehydrated (as
described above) followed by heat-induced, epitope
retrieval performed in a pressure cooker for 45 min in
pH 6.0 Citrate buffer (Biocare Medical). Sections were
allowed to cool for 20 min at room temperature. Sec-
tions were immersed for 30 min at room temperature in
blocking solution in 0.1 M Tris-HCl (pH 7.5) containing
3% BSA and 20% fetal bovine serum (FBS). Sections
were rinsed twice with PBS at room temperature. Posi-
tive control sections were incubated with 0.5 mg/ml
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(pH 7.5), 1 mM MgCl2 and 1 mg/ml BSA at room tem-
perature for 10 min. The sections were incubated in the
TUNEL reaction mixture (as supplied by In Situ Cell
Death Detection kit, Roche) for 60 min at 37°C in a
humidified chamber. Sections were washed three times
for 5 min in PBS, and then incubated for 10 min at
room temperature in 0.3% H2O2 diluted in methanol.
To block nonspecific binding of the anti-fluorescein
antibody, the sections were incubated in blocking solu-
tion (as described above) for 30 min at room tempera-
ture then rinsed in PBS. Sections were incubated in
Converter-POD (as supplied by In Situ Cell Death
Detection kit, Roche), diluted in blocking solution (as
described above), for 30 min at 37°C in a humidified
chamber. Sections were rinsed three times for 5 min
each in PBS. The signal was developed using the Vector
DAB substrate kit, according to the manufacturers’
instructions. Sections were dehydrated (as described
above) and mounted using Permount (Fisher).
Immunohistochemistry of tumors and mouse tissue
For immunohistochemistry (IHC), tissues were collected
and placed in 10% neutral buffered formalin equal to 20
times the tissue volume (Fisher). Tissues were incubated
overnight at room temperature and then processed by
standard formalin fixation, paraffin embedding and sec-
tioning by The Center for Gene Therapy Histology Core
Facility, Tulane University. Immunohistochemistry was
performed as per the Vectastain staining kit (anti-rabbit,
PK6101; anti-mouse PK6102, Vector Laboratories).
Briefly, 5 μm sections were rehydrated (as described
above) followed by heat-induced, epitope retrieval per-
formed in a pressure cooker for 25 min. in Tris Buffer,
pH 9 (Biocare Medical) or 45 min in pH 6.0 Citrate buf-
fer (Biocare Medical). To inactivate the endogenous per-
oxide, slides were incubated in 0.3% hydrogen peroxide
followed by a 10 min wash in dH2O then washed 3 × 3
min. each in PBS. Sections were incubated in blocking
buffer (10% normal goat serum diluted in PBS) for 30
min. at room temp and subsequently incubated with pri-
mary antibody diluted in blocking buffer overnight at 4
deg. Primary monoclonal antibodies used were rabbit
anti-human Ki-67 (SP6, Thermo Scientific), rabbit anti-
human E-cadherin (24E10, Cell Signaling), rabbit anti-
human Vimentin (SP20, Vector Laboratories), rabbit
anti-human Estrogen receptor (SP1, Thermo Scientific),
and anti-human HNA (MAB1281, Chemicon). Primary
polyclonal antibodies used were rabbit anti-human b-
catenin (9563, Cell Signaling), rabbit anti-human fibro-
nectin (ab2413, Abcam), and rabbit anti-human (human
specific) cytokeratin 8 (ab52949, Abcam). The following
day, sections were washed 2 × 5 min. in PBS-T. Biotiny-
lated secondary antibody was added to the sections for
an incubation period of 30 min, followed by 2 × 5 min.
washes in PBS-T. Streptavidin/biotin HRP-conjugate
was added to the sections for an incubation period of 30
min. at room temperature followed by 2 × 5 min.
washes in PBS-T. The signal was developed using the
Vector DAB substrate kit, according to the manufac-
turers’ instructions. Sections were dehydrated (as
described above) and mounted using Permount (Fisher).
Staining was visualized using a bright field microscope
and IP lab software. For quantitation, five randomly
selected bright field microscope images (magnification
200×) per sample were obtained as described above.
The total cell number in each image was calculated by
counting hematoxylin-positive cells using Image J parti-
cle count command, and DAB-positive cells were also
counted the same way after performing color deconvo-
lution command and expressed as % positive cells.
Histological scoring
Her 2 expression within the tumors was measured by
IHC and assessed using the histoscore method devel-
oped by Allred et. al. [25]. Briefly, a proportion score
and an intensity score were determined for each tumor
sample. The proportion score represented the percen-
tage of positively stained cells (0 = none; 1 = < 5%; 2 =
5-25%; 3 = 26-50% 4 = 51-75% 5 = > 75%) [26]. The
intensity score represented the staining intensity in posi-
tively stained cells (0 = none; 1 = + weak; 2 = ++ inter-
mediate; 3 = +++ strong). The overall expression of
Her2 in each tumor sample was reported as a histo-
score, calculated by the sum of the proportion score (0-
5) and the intensity score (0-3) for a range between 0
and 8, with a maximum possible score of 8 [25].
Results
Isolation of tumorspheres from human breast core
biopsies
The purpose of this study was to establish a reproduci-
ble method for the isolation of primary tumorspheres
from patient core biopsies and characterization of subse-
quent tumor formation upon transplantation into nude
mice. The establishment of a hetero-transplantation
model, as described in this report, provides an improved
a n dt r a n s l a t a b l em u r i n em o d e lf o rt h es t u d yo fh u m a n
breast cancer metastasis. Patient core biopsies were
obtained using a 14-gauge spring-loaded gun, yielding
15-20 mg of tissue per biopsy. Tumorspheres were
derived from patient core biopsies under serum-free,
non-adherent culture conditions as described in Materi-
als and Methods. The ER/PR/Her2 status differed in the
patient samples (Table 1). The majority of patient sam-
ples were Grade 2 or higher and diagnosed as invasive
ductal carcinoma (IDC) (Table 1). Tumorspheres were
successfully isolated from all patient samples and ranged
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tumorspheres demonstrated a cell surface marker phe-
notype CD44
+/CD24
med/low/ESA
+ by immunocytochem-
istry (Additional file 1: Figure S1a-b), a phenotype
previously determined to be tumorigenic in immune-
deficient mice [27].
Tumor formation and serial transplantation in NUDE mice
To establish the presence of tumor-initiating cells within
the isolated tumorspheres, cells were injected into the
mammary fat pad of female NUDE mice in combination
with Matrigel and mice were monitored for tumor for-
mation. Since previous in vitro experiments suggested
dissociation of the tumorspheres caused decreased viabi-
lity of the cells (data not shown), non-dissociated
tumorspheres were injected into the mammary fat pad.
Based on cell counts performed during previous in vitro
experiments, an estimate of 50-100 cells comprised a
tumorsphere of 100 μm in diameter. All of the primary
tumor samples stained with H+E were histologically
evaluated by a pathologist (K.M.). The tumor formation
capabilities of tumorspheres isolated from samples 1-3
were conducted in NOD/SCID female mice (data not
shown). Tumor formation for samples 1-3 was not
observed 3 months post-injection and extension of the
experiment was terminated because of a high incidence
of thymic masses in the NOD/SCID mice that a pre-
vious study described as lymphoma development [28].
Consequently, subsequent experiments were performed
with the mouse strain to Nu/Nu (NUDE). Injection of
Matrigel alone into the mammary fat pad of NUDE
mice did not result in tumor formation (Figure 1B,
arrows). Injection of 50 tumorspheres (estimated total
cells injected: 1-5 × 10
3 cells) isolated from samples 5-9
in combination with Matrigel into the mammary fat pad
resulted in formation of small, palpable tumors within 3
months post-injection (Figure 1C-D. arrows) that were
maintained until the end of the experiment (approx. 9-
12 months post-injection). Tumorspheres isolated from
sample 4 did not form tumors when injected into the
mammary fat pad in combination with Matrigel (Table
1). Tumorspheres were re-isolated from the tumors
formed in the mammary fat pad by employing the same
serum-free, non-adherent culture conditions used to iso-
late tumorspheres from patient core biopsies. Serial
transplantation was demonstrated by the injection of re-
isolated tumorspheres into the mammary fat pad of
NUDE mice in combination with Matrigel. Samples 5-9
were serially transplanted in this manner three times
through NUDE mice. In summary, the in vitro selection
Table 1 Formation of primary tumor and metastasis in NUDE mice implanted with tumorspheres isolated from human
breast core biopsies.
Sample Formation
in mice
Latency to palpable
tumor formation
Passage in
Mice
Metastasis Metastatic
Latency
Age Diagnosis Grade ER/PR/Her2
Status
4 0/2 N/A N/A Not
Determined
N/A 56
years
IDC Grade
2
ER
+/PR
+/Her2
-
5 5/6 74 days Yes Yes 254 days 44
years
IDC Grade
3
ER
+/PR
+/Her2
-
6 6/6 47 days Yes Yes 232 days 62
years
IDC with
lymphovascular
invasion
Grade
2
ER
+/PR
+/Her2+
7 5/6 72 days Yes Yes 214 days 77
years
IDC Grade
2
ER
-/PR
-/Her2
-
8 4/6 35 days Yes Yes 248 days 63
years
IDC Grade
2
ER
+/PR
+/Her2
-
9 6/6 46 days Yes Yes 279 days 66
years
IDC Grade
1
ER
+/PR
+/Her2
Tumor formation in NUDE mice following bilateral injections into the mammary fat pad of tumorspheres that were derived from the original patient biopsy. The
latency or palpable tumor formation is indicated in number of days post-injection of tumorspheres into the mammary fat pad. ‘Passage in mice’ indicates that
the primary tumor could be serially transplanted into mice to form subsequent primary tumors following in vitro formation of tumorspheres prior to injection
into the mammary fat pad. Metastasis was determined by detection of human chromosome 17 by PCR using DNA isolated from mouse organs collected from
mice injected with tumorspheres into the mammary fat pad. Metastatic latency is the average number of days between the injection of tumorspheres into the
mammary fat pad and the detection of metastatic lesions in all organs analyzed by H+E staining
B. C.
Tumor Matrigel
D.
Tumor
A.
Figure 1 Tumor formation in the mammary fat pad upon
injection of human tumorspheres. A. Light microscopy of a
representative tumorsphere isolated from a patient core biopsy
following in vitro culture for 10 days. B. Injection of Matrigel alone
into the 3rd mammary fat pad of female NUDE mice. C, D. ≤5×
10
3 cells derived from the original patient biopsy were injected into
the 3rd mammary fat pad in the form of ‘tumorspheres’ (with
Matrigel) and resulted in formation of small, palpable tumors within
3 months injection with an approximate, sustainable tumor volume
of 100 mm
3
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biopsies contained bTICs that formed small tumors
when injected into the mammary fat pad of NUDE
mice. These tumors were serially transplantable through
NUDE mice upon re-isolation of tumorspheres in vitro
and re-injection of tumorspheres into the mammary fat
pad of mice.
Characterization of tumors formed in the mammary fat
pad upon injection of tumorspheres
H+E staining was performed on sections of the primary
tumors removed from the mammary fat pad. The edges
of the tumors were often occupied by a dense popula-
tion of cells as compared to areas closer to the center of
the tumor that were less dense (Figure 2A, arrows).
Tumors consisted of small tumor cells with pleomorphic
nuclei that did not exhibit tubule formation (Figure 2A-
B). IHC was performed on sections of the tumors to
determine the number of proliferating cells using a rab-
bit monoclonal ki67 antibody. Over 40% of the cells
were proliferating in sample 6 and 9, and over 60% of
the cells were proliferating in samples 5, 7, and 8 (Fig-
ure 2C, E). To understand how a small tumor size could
be maintained in the context of significant proliferation,
terminal deoxynucleotidyl transferase (TdT)- mediated
dUTP nick end labeling (TUNEL) was performed on
sections of the tumors to determine the rate of apopto-
sis. The rates of apoptosis for samples 5-9 were similar
to the rates of proliferation for each sample (Figure 2D,
F) indicating a large degree of cell turnover in the
tumors. In contrast, rapidly growing MCF-7 breast
tumor xenografts did not display significant apoptosis
(Figure 2F). A section from an MDA-MB-231 breast
tumor xenograft incubated with 4 U/ml of DNase I at
37°C for 10 min was used as a positive control (Figure
2F, positive control).
The tumors were analyzed for the expression of a
wide range or markers by IHC. Sections of MCF-7 and
MDA-MB-231 tumor xenografts were used as controls
for positive and negative staining by IHC for all antibo-
dies (Additional file 2: Figure S2a-l). Expression levels
for each marker were quantified using the MachBiopho-
tonics ImageJ 1.42I program (as described in the Materi-
als and Methods). All tumor samples were negative for
estrogen receptor a (ERa) and the mesenchymal marker
vimentin (data not shown). The cell adherens junction
protein E-cadherin is normally expressed in the mem-
brane of differentiated epithelial cells and more differen-
tiated breast cancer cells. E-cadherin was observed at
variable levels in the cytoplasm and nucleus in all tumor
samples but not within the cell membrane (Figure 3A,
H). b-catenin, a central mediator of the WNT pathway,
binds to E-cadherin at the membrane in conjunction
with a complex of proteins connecting the adherens
junction to components of the cytoskeleton [29,30]. In
the absence of membrane E-cadherin, b-catenin is either
rapidly degraded or can translocate to the nucleus upon
activation of WNT signaling. In corroboration with the
aberrant cytoplasmic and nuclear E-cadherin staining,
localization of b-catenin was also observed at variable
levels in the cytoplasm and nucleus of all the tumor
samples (Figure 3B, H). Although all the tumor samples
were negative for vimentin, another mesenchymal mar-
ker fibronectin was detected in all samples (Figure 3C,
H). Her2/neu was detected by IHC in all tumor samples
however the extent of expression was highly variable
between samples (Figure 3D, H). In addition to quantifi-
cation using the MachBiophotonics ImageJ 1.42I pro-
gram, Her2/neu expression within the tumor samples
was expressed as a histoscore (as described in the Meth-
ods) (Figure 3I). Based on the reported histoscores, sam-
ple 7 exhibited the lowest expression of Her2 whereas
sample 5 exhibited the highest expression of Her2 as
compared to the other samples (Figure 3I). The detec-
tion of Her2/neu staining by IHC in the experimental
tumors is not equivalent to the clinical diagnosis of
Her2/neu positive tumors, which is based predominantly
upon Her2/neu gene amplification. All tumors showed
positive staining using an antibody to broad-spectrum
cytokeratins at variable levels between tumors (data not
shown) indicating the presence of epithelial lineage cells
in the tumor. IHC for cytokeratin 8 and cytokeratin 14
was performed to determine the presence of luminal
and myoepithelial cell lineages, respectively, within the
tumors. Cytokeratin 8 was detected in all samples at
variable levels (Figure 3E, H) whereas cytokeratin 14
was only detected in sample 5 and 9 (Figure 3F, H).
T h e s ed a t ai n d i c a t et h a tt u m o r sw e r ec o m p r i s e do f
mixed luminal and myoepithelial lineage tumor cells
with some tumors negative for myoepithelial lineage
tumor cells. Recently, aldehyde dehydrogenase (ALDH)
has been implicated as a stem cell marker for both nor-
mal mammary cells and breast cancer cells [31,32]. IHC
using a rabbit monoclonal antibody against ALDH1A1
demonstrated less than 20% of cells in all tumors
expressed ALDH1A1 and no expression was detected in
tumors formed from sample 8 (Figure 3G, H). These
data, along with the cytokeratin staining, indicate that
the tumors formed upon injection of tumorspheres into
the mammary fat pad of NUDE mice did not entirely
retain the primitive features of the tumorsphere [16,33],
but instead exhibited marked heterogeneity in expres-
sion of lineage specific epithelial and mesenchymal mar-
kers. To confirm that tumors contained cells of human
origin, IHC was performed using a mouse monoclonal
antibody against human nuclear antigen (HNA) [34,35].
Sections of a human MDA-MB-231 breast tumor xeno-
graft was used as a positive control for HNA staining
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used in place of the HNA primary antibody step for
staining tumors formed upon injection of tumorspheres
(Additional file 3: Figure S3b); sections of a mouse kid-
ney incubated with the HNA antibody from a non-
tumor bearing animal was also used as a negative con-
trol (Additional file 3: Figure S3c). In all tumors (sam-
ples 5-9), a majority of the cells stained positive for
H N Aa ss h o w ni nt h er e p r e s e n t a t i v em i c r o g r a p hf o r
sample 6 (Additional file 3: Figure S3d). Metastatic
lesions within the liver and lung were also positive for
HNA (Additional file 3: Figure S3e and f, respectively).
Metastatic human cancer cells detected in mouse tissues
Micrometastasis of human cancer cells to mouse kidney,
liver, lung, brain and femurs (bone marrow) was
assessed at 3 months post-injection using PCR to detect
human chromosome 17 in the mouse tissues. Although
no visual macrometastatic lesions were observed within
any of the organs at 3 months post-injection, human
DNA was detected in the kidneys, liver, lung, bone mar-
row (Figure 4A), and brain (data not shown). As a nega-
tive control, DNA was isolated from the organs of a
mouse injected with Matrigel alone into the mammary
fat pad; no signal was detected (Figure 4B). H+E staining
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Figure 2 Morphology, proliferation and apoptosis within primary tumors formed upon injection of tumorspheres. A, B. H+E staining of
5 μm paraffin-embedded tumor sections derived from patient Sample 5 at 40× and 200×, respectively. C, E. IHC and quantitation for Ki67 were
performed on 5 μm paraffin-embedded tumor sections derived from patients Samples 5-9. Ki67 positive cells and total number of cells were
counted using Image J software in five randomly microphotographed images from each tumor sample and represented as the mean % positive
cells with SD. D, F. TUNEL staining and quantitation (as described above) for apoptosis. MDA-MB-231 human breast cancer xenograft incubated
with 4 U/ml DNase I was used as a positive control for TUNEL. Values are reported as mean +/- SD.
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brain and kidney (Figure 4C-F, respectively).
Data from Figure 4 demonstrated that by 3 months
post-injection of tumorspheres into the mammary fat
pad, tumor cells had disseminated to distant organs. By
8 months post-injection, macrometastatic (visual) lesions
were observed in the lung, liver and kidney for samples
5-9 (Figure 5A-C, respectively). H+E staining performed
on sections of organs with visual metastatic lesions at
the time of necropsy confirmed the presence of large
metastatic lesions within the lung, liver and kidneys
(Figure 5D-F, respectively).
Organ tropism of the metastatic cells and the metastatic
burden within the mouse organs
Paraffin-embedded sections of lungs, livers, kidneys and
brains from samples 5-9 were stained with H+E to
further determine the metastatic potential of the tumor-
spheres injected into the mammary fat pad. Since
tumorspheres isolated from sample 1-3 did not form
tumors in the mammary fat pad of NOD/SCID mice,
the metastatic potential for these samples was not
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Figure 3 Expression of markers for epithelial and mesenchymal lineages in tumor samples. A-G. Representative IHC demonstrating
patterns of expression of E-cadherin, fibronectin, Her2/neu, cytokeratin 8, cytokeratin 14, and aldehyde dehydrogenase 1 (ALDH1) in tumors
formed upon the injection tumorspheres into the mammary fat pad of female NUDE mice. 200× magnification in all panels. H. Quantitation of
positive staining and total number of cells were counted using Image J software in five randomly microphotographed images from each tumor
sample and represented as the mean % positive cells with SD. I. Histological scoring of Her 2 expression within tumor samples. Values are
reported as mean +/- SD.
A. B.
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Figure 4 Detection of micrometastasis of human cancer cells in
mouse tissues. A. PCR for a centromeric region in human
chromosome 17 was used to detect human cells in mouse organs
isolated from mice injected with tumorspheres into the mammary
fat pad 3 months post-injection. Human DNA was detected in the
lungs, kidneys, brain, bone marrow, and liver. DNA isolated from
MCF-7 cells and mouse tail was used as a positive and negative
control, respectively. B. PCR for DNA isolated from organs collected
from a mouse injected with Matrigel alone was also used as a
negative control. C-F. Micrographs representing micrometastasis in
the lung, liver, brain and kidney, respectively, collected from mice
previously injected with tumorspheres. 100× magnification in all
panels. Arrows indicate micrometastases surrounded by normal
mouse tissue.
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Page 8 of 16determined. A comprehensive analysis of metastasis was
performed to: 1) determine the percentage of all organs
examined (lung, kidney, brain, liver) that exhibited
metastases for each of samples 5-9 (overall metastatic
spread); 2) compare tropism of each sample to different
organs, and; 3) quantitate the relative metastatic burden
within each organ for each sample as a measure of the
ability of metastatic cells to colonize organ sites and
grow into larger lesions. The total number of organs
with detectable metastases was counted to determine
the overall metastatic spread for each sample. The data
was further separated by the particular organ with
detectable metastases (lung, liver, kidney and brain) to
determine tropism. The metastatic burden within each
organ was then quantified as described in the material
and methods. The number (n) of lungs, kidneys, brains
and livers analyzed for each sample is indicated in Fig-
ure 6C-G.
The percentage of all organs examined with metastasis
(overall metastatic spread), without regard to the size of
the metastatic lesions, was comparable between all sam-
ples (Figure 6A). Sample 7 demonstrated the lowest
(71%), and sample 9 demonstrated the highest (100%)
overall metastatic spread. Analysis of the percentage of
organs with metastasis (without regard for the size of
the metastatic lesions) revealed qualitative differences in
the organ tropisms of the samples. Samples 5 and 9
exhibited the highest tropism to lung and brain as com-
pared to the other samples and sample 9 also exhibited
higher tropism to liver (100%) than any other sample
(Figure 6B). Sample 5 additionally demonstrated the lar-
gest % metastatic burden in the lung compared to other
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Figure 5 Macrometastasis in the organs of mice injected with
tumorspheres into the mammary fat pad. A-C. Representative
visual macrometastatic lesions detected in the lung, liver and
kidney, respectively, 10 months post-injection of tumorspheres into
the mammary fat pad of NUDE mice. D-F. H+E staining performed
on 5 μm paraffin-embedded section of a lung, liver and kidney,
respectively, illustrates macrometastatic lesions in the organs.
Metastatic lesion indicated by £; normal mouse tissue indicated by
§. 100× magnification in all panels.
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Figure 6 Quantitation of the organ tropism of the metastatic cells and the metastatic burden within the mouse organs. A. Comparison
of the percentage of total organs that contained metastatic cells (Overall Metastatic Spread) for samples 5-9 as assessed by morphological
analysis of H+E stained sections. The total number of mouse organs analyzed is indicated by n above each bar. B. Comparison of the percent of
lungs, kidneys, brains and livers that contained metastatic cells (Organ Tropism) for samples 5-9 as assessed by morphological analysis of H+E
stained sections. C-E. Graphical representation of the metastatic burden calculated for the total number of lungs, kidneys, brains and livers that
were analyzed from mice injected with sample 5-9. The number of mouse organs analyzed is indicated by n in each graph. Each bar represents
the calculated metastatic burden for one organ. The metastatic burden in each organ was calculated by dividing the pixels present in the
metastatic lesion/s (x pixels) by the total pixels comprising the field of view (y pixels) then multiplying by 100 [(x pixels/y pixels)*100], resulting in
a percent value. The percent metastatic burden was calculated from the means from 5 fields of view (100× magnification) per organ analyzed.
Values are reported as mean +/- SD.
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Page 9 of 16tumor samples (compare lung % metastatic burden in
Figure 6Cto Figures 6D-G). Although sample 9 demon-
strated the highest tropism to liver (Figure 6B), the
metastatic burden in the liver did not exceed 10% (Fig-
ure 6G) indicating that although sample 9 metastasized
to liver in 100% of animals, the metastatic tumor cells
did not develop into large metastatic lesions. In contrast,
although sample 7 showed the lowest tropism to liver
compared to other samples (60%, Figure 6B), the metas-
tasized tumor cells yielded the greatest metastatic bur-
den in the liver compared to other samples (Figure 6E).
Sample 7 demonstrated the lowest tropism to the brain
(Figure 6B) although the metastatic burden in the brain
was comparable to the other samples (Figure 6E). Sup-
plemental Figure 4 represents the % metastatic burden
in each tissue for each sample as a function of the time
the organs were removed after initial injection of tumor-
spheres into the mammary fat pad (Days post-injection).
An increase in metastatic burden in any of the organs
did not correlate with the number of days post-injection
(Additional file 4: Figures S4a-e). However, sample 7
demonstrated larger metastatic lesions at earlier time
points as compared to the other samples (Additional file
4: Figure S4c).
Characterization of the metastatic cells within the mouse
organs
It is hypothesized that tumor cells acquire metastatic
potential following an epithelial to mesenchymal transi-
tion (EMT) that permits local invasion and migration to
distant metastatic sites. Once cells arrive at these meta-
static sites, it is further hypothesized that tumor cells
may undergo a reversion to reacquire epithelial charac-
teristics that will permit survival and outgrowth at the
ectopic site [30,36]. Therefore the expression of E-cad-
herin and b-catenin, two important modulators of EMT,
was assessed by IHC within the metastatic lesions in the
lung and liver. The localization of E-cadherin and b-
catenin in the lung and liver was markedly different
than the localization in the primary tumor (see Addi-
tional file 5: Table S1 for comprehensive comparison of
marker expression profiles between primary tumor and
metastatic lesions). In contrast to the predominantly
cytoplasmic and nuclear localization of E-cadherin in
the primary tumors, E-cadherin was detected in the
membrane of the metastatic cells in the lung and liver
although not all metastatic cells demonstrated E-cad-
herin staining (Figure 7A and 7B). In the liver, E-cad-
herin expression was most consistently observed in
metastatic cells within close proximity to resident hepa-
tocytes (Figure 7B, black arrow). Interestingly, hepato-
cytes within close proximity to metastatic cancer cells
demonstrated stronger expression of E-cadherin in the
membrane as compared to hepatocytes not proximal to
metastatic cancer cells (Figure 7B, red arrow). Similar to
localization of E-cadherin, b-catenin expression was also
detected predominantly in the membrane of the meta-
static cells in the lung and the liver (Figure 7C and 7D)
in contrast to the cytoplasmic and nuclear localization
in the primary tumor. The pattern and intensity of b-
catenin staining was similar to that of E-cadherin within
the same lung tissue samples (Figure 7C, black arrow).
b-catenin was most strongly expressed in the membrane
of metastatic cells within close proximity to hepatocytes
in the liver, similar to the results with E-cadherin (Fig-
ure 7D, black arrow). Fibronectin, a component of the
extracellular matrix (ECM), exhibited variable expression
within metastatic lesions in the lung and the liver (Fig-
ure 7E and 7F). All metastatic lesions in the liver did
not express ERa, consistent with the lack of ERa
expression in the primary tumors (Figure 7H). However,
metastatic lesions in the lung of mice injected with
tumorspheres isolated from samples 6 and 8 demon-
strated heterogeneous re-expression of ERa (Figure 7G,
arrow).
Discussion
Current research implies the presence of a population of
cells in breast tumors with tumor-initiating capabilities.
A number of cell surface markers have been used to
sort for breast cancer cells with tumor-initiating capa-
city, including CD44 [6], CD133 [37], ALDH [31,38],
CD90 [39,40], and CD117 (KIT) [41]. However, attempts
to eliminate artifact may result in the biased selection of
a small sub-population of cells present in disaggregated
tissue. Presented in this study is an efficacious model
for the in vitro isolation of tumorspheres, containing
breast tumor-initiating cells, from human breast core
biopsies. Injection of isolated tumorspheres into the
mammary fat pad of NUDE mice resulted in formation
and maintenance of small, palpable tumors that exhib-
ited elevated proliferation and apoptosis. Within 8
months post-injection, widespread metastasis to mouse
organs occurred most notably to liver, lung, and kidney.
The cells within the tumors present in the mammary fat
pad displayed heterogeneous expression of a range of
markers for epithelial and mesenchymal differentiation
that included cytokeratins, E-cadherin, b-catenin, fibro-
nectin, as well as Her2/neu. Histological heterogeneity
was observed both within individual tumors, and
between tumors formed from tumorspheres isolated
from different patient samples. Whereas primary tumors
did not exhibit E-cadherin staining in cell membranes, a
subset of tumor cells that hadm e t a s t a s i z e dt ot h el u n g
and the liver exhibited a re-distribution of E-cadherin to
the membrane. These data describe a novel hetero-
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profile that recapitulates the development of metastasis
in human breast cancer patients.
Tumorspheres were successfully isolated from all
breast core biopsies including samples 1-3, which were
not included in the data presented due to the lack of
tumor formation and development of thymic lymphoma
in NOD/SCID mice (as described in the Results section).
Samples 5-9 tumorspheres were derived from patients
with invasive ductal carcinoma (IDC), similar to other
reports investigating the tumorigenic potential of breast
cancer cells isolated as tumorspheres in vitro [16,33].
Although FACS has been used to isolate tumorigenic
breast cancer cells from other breast cancer subtypes
such as inflammatory breast cancer and lobular carci-
noma [27], there are no reports demonstrating the suc-
cessful isolation of tumor-initiating cells as
tumorspheres from these breast cancer subtypes. When
the host was changed to NUDE mice, the methods
described herein reproducibly resulted in tumorsphere
formation in vitro, and in tumor formation for all sam-
ples derived from primary breast core biopsies irrespec-
tive of ER/PR/Her2 status, tumor grade or stage.
Tumorsphere number and size varied between samples,
however differences could not be correlated with ER/
PR/Her2 status, tumor stage or grade.
Tumorspheres isolated under select culture conditions
likely contain a heterogeneous population of cells most
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Figure 7 Expression of markers for epithelial and mesenchymal lineages in metastatic lesions of lung and liver. A-B. IHC performed on
5 μm paraffin-embedded sections of a lung and liver using a monoclonal anti-human antibody to E-cadherin. C-D. IHC performed on 5 μm
paraffin-embedded sections of a lung and liver using a polyclonal anti-human antibody to b-catenin. E-F. IHC performed on 5 μm paraffin-
embedded sections of a lung and liver using a polyclonal anti-human antibody to fibronectin. G-H. IHC performed on 5 μm paraffin-embedded
sections of a lung and liver using a monoclonal anti-human antibody to ERa. G. Inset panel (bottom left) demonstrates negative staining in
normal lung cells in proximity to the metastatic lesion in the lung. 200× magnification in all panels.
Marsden et al. BMC Cancer 2012, 12:10
http://www.biomedcentral.com/1471-2407/12/10
Page 11 of 16of which will not likely have tumor-initiating capabil-
ities. Therefore tumor formation upon the injection of a
minimal number of cells that were not selected on the
basis of epithelial origin or differentiation potential indi-
cated the presence of tumor-initiating breast cancer
cells within the tumorspheres. The injection of non-dis-
aggregated tumorspheres, as opposed to single cell sus-
pensions, establishes a novel method for the
investigation of tumorigenicity in vivo.T h ea b s e n c eo f
mechanical and/or enzymatic stress during preparation
of the cells for injection improved the tumor cell viabi-
lity. Therefore the injection of non-dissociated tumor-
spheres, in combination with the immune-deficient
mouse model employed (NUDE mouse strain), contribu-
ted to the high tumor engraftment rates observed. How-
ever, future studies should determine differences in
tumor formation and metastatic potential between single
cell suspensions and non-disaggregated tumorspheres.
Differences detected may reveal the effects of cell selec-
tion bias based on methodologies employed when pre-
paring cells for injection.
The small primary tumor volume observed in the
mammary fat pad suggested a low level of tumor cell
proliferation. However the number of proliferating cells
detected by Ki67 staining was high in all tumor samples.
This high proliferation was offset by a number of cells
undergoing apoptosis. This equilibrium between prolif-
eration and apoptosis provided an explanation for the
formation and long-term propagation of the small, palp-
able tumors, indicating the tumors were persisting in a
state of tumor dormancy. However it also raised the
question as to why the high level of proliferation
observed in the tumors did not eventually overcome the
apoptosis and result in larger tumor volumes with time.
One possible explanation could be the inability of
tumors to initiate neoangiogenesis that was manifest in
high rates of apoptosis and proliferation that culminated
with tumor dormancy [42,43]. Failure of the injected
cells to efficiently recruit mouse stromal cells/endothe-
lial cells would lead to nutrient and oxygen deprivation
that would result in high levels of apoptosis to compen-
sate for a high proliferation of the tumor cells. Alterna-
tively, this disruption in homeostasis may occur as a
later event during tumor progression, upon sufficient
acquisition of somatic mutations within the differen-
tiated progeny. Nonetheless, the metastatic phenotype
demonstrated in this study implies that metastasis is an
early event in tumorigenesis; conferring implications
that challenge the linearity of breast tumor progression.
Traditional xenograft models derived from established
breast cancer cell lines (e.g. MCF-7, MDA-MB-231) dis-
play fairly homogeneous organization, morphology, and
protein expression patterns. In contrast, characterization
of the tumors derived from primary tumorspheres
presented here revealed heterogeneity among samples in
morphology and marker expression. Because the tumor-
spheres exhibited stem-like properties, it might be
expected that tumors in mice derived from the tumor-
spheres would exhibit similar morphology as the patient
tumors. Because the tumorspheres exhibited stem-like
properties, it might be expected that tumors in mice
derived from the tumorspheres would exhibit similar
morphology as the patient tumors. Although the human
breast tumor samples ranged from grade 1-3, the
tumors in the mammary fat pad did not exhibit all of
the morphological characteristics of the patient tumors,
such as tubule formation and ER and Her2 expression.
This discrepancy is likely a result of the microenviron-
ment within the mammary fat pad that is mostly devoid
of the stromal and cellular components present in
human mammary tissue, and instead is composed pre-
dominantly of adipose tissue. It is possible that the
inclusion of human stromal/cellular components with
the tumorspheres would more accurately recapitulate
the microenvironment within human mammary tissue
resulting in tumors that might exhibit tubule formation,
ER/PR expression and other characteristics of low grade,
more differentiated. In general, the edges of the tumors
were lined with dense areas of cells that were also
observed within the tumors as a dense ring of cells sur-
rounding a more diffuse distribution of tumor cells (Fig-
ure 2). Although the expression patterns of most
markers used in the characterization of the tumors did
not correspond to this evident cellular organization, the
expression of b-catenin did correlate with this organiza-
tion displaying strong expression in the ring of cells
encapsulating the diffuse population of cancer cells. All
tumors in the mammary fat pad were negative for ERa
despite the varied ERa status of the patient samples.
During an EMT in breast cancer, E-cadherin expression
in the membrane is reported to be lost or re-localized
to the cytoplasm [29,44]. Consistent with a mesenchy-
mal phenotype, in the primary tumors E-cadherin and
b-catenin expression was localized in the cytoplasm and
nucleus (Figure 3). Given that loss of E-cadherin expres-
sion in breast cancer is associated with an EMT and
with the metastatic process, the unique expression pat-
tern of E-cadherin in the present tumor model that
exhibits a metastatic phenotype warrants further study.
Human metastatic cancer cells were detected by PCR
at 3 months post-injection of tumorspheres into the
mammary fat pad within the lung, liver, kidney, brain
and femur (Figure 4). However the development of large
metastatic lesions was observed by H+E staining in the
lung, kidney and liver only. Comparison of the organ-
specific percent metastasis to the metastatic burden
within each organ revealed interesting results. Although
sample 7 demonstrated the lowest percent metastasis
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metastatic burden within each organ was comparable to
or more often higher on average as compared to the
other samples. In contrast, sample 9 demonstrated the
highest percent metastasis overall and within the organs
analyzed, however the percent metastatic burden within
each organ was minimal compared to the other samples.
These conflicting results elucidate a potential shortcom-
ing in the current methods employed for predicting
metastatic disease. The ability of cancer cells to metasta-
size from the primary site to distant sites may not accu-
rately reflect the actual metastatic potential of the cells.
Rather, understanding and predicting the adaptation of
the cells that have arrived at the distant site of metasta-
sis, may more accurately determine the potential for the
development of overt metastatic disease. Samples 5 and
9, the only tumor samples derived from patient biopsies
with clinical diagnosis of triple negative (ER
-/PR
-/Her2
-),
demonstrated the highest average metastatic burden
within the organs. This observation may imply a growth
advantage at distant sites for metastatic cells derived
from triple negative tumors, although additional samples
would be needed to demonstrate statistical significance.
Despite the detection of metastasis by H+E staining in
60%-100% of brains analyzed, the metastatic burden was
on average between only 1-3%. The blood-brain barrier
(BBB) consists of tight junctions and adherens junctions
between the brain endothelial cells, restricting the pas-
sage of substances from the bloodstream into the brain
[45]. Impedance of entry into the brain by the BBB may
contribute to the apparent extended dormancy period of
the metastatic cells present in the brain, in combination
with other influencing factors. Overall, the long duration
from the time of detection of cancer cells in the organs
(by PCR and/or histological staining) to the develop-
ment of visual macrometastasis in mouse organs was
similar to the delay in development of measurable
metastasis in breast cancer patients following diagnosis
of primary breast tumors [46,47]. The extended latency
between the injection of tumorspheres and the develop-
ment of macroscopic metastatic lesions is a limitation of
this model. The injection of a higher number of cells
may increase the time to tumor formation and the
tumor volume in the mammary fat pad, however we
speculate that the observed metastatic latency would not
be affected. The organ microenvironment and intrinsic
properties of the disseminated cells likely predominantly
contribute to the observed metastatic latency. However
secreted factors from the primary tumor within the
mammary fat pad could also influence metastatic pro-
gression, therefore an increase in tumor volume may
affect the proliferative state of disseminated tumor cells
at distant sites. Future studies investigating the effects of
larger tumor volumes on metastatic latency, possibly by
the injection of increasing numbers of cells into the
mammary fat pad, may elucidate the influence of
secreted factors from the primary tumor on dissemi-
nated cancer cells. The detection of micrometastases in
an array of organs with the development of macrome-
tastases in only a select few of those organs suggests
that mechanical/stochastic forces may permit entry of
cancer cells into a range of organs; however metastatic
cells will only survive and develop into overt lesions
when present within a permissive, conditioned meta-
static niche [20].
Whereas cytoplasmic and nuclear localization of E-
cadherin and b-catenin was observed in the primary
tumors, E-cadherin and b-catenin were re-expressed in
the membrane in a subset of metastatic cells in the lung
suggesting a possible reversion back to an epithelial phe-
notype (a mesenchymal to epithelial transition) [36,48].
E-cadherin and b-catenin expression was predominantly
observed in the membrane of metastatic cells proximal
to hepatocytes in the liver. Furthermore, hepatocytes
proximal to metastatic cancer cells demonstrated stron-
ger E-cadherin expression as compared to hepatocytes
not within close proximity to metastatic cancer cells.
Chao et al. demonstrated re-expression of E-cadherin in
the membrane of MDA-MB-231 breast carcinoma cells
in vivo and in vitro when in close proximity to hepato-
cytes [49]. Additionally, in prostate cancer models of
metastasis to the liver, E-cadherin was shown to accu-
mulate at the interface with hepatocytes [50,51]. These
findings further support the importance of crosstalk
between the cancer cells and native cells present within
the organ. Fibronectin, a component of the extracellular
matrix (ECM), plays an important role in cell migration,
adhesion, maintenance of cell shape and wound healing.
Fibronectin-dependent signaling has been linked to can-
cer cell dormancy, involved in the quiescent to prolifera-
tive switch [52,53]. Many of the smaller metastatic
lesions in the liver did not demonstrate expression of
fibronectin, however fibronectin was found variably
expressed within the larger metastatic lesions. This
observation could implicate fibronectin signaling as a
possible mechanism involved in the development of
macrometastatic lesions within the liver. The metastatic
lesions within the liver were negative for ERa in all
samples, consistent with thel a c ko fe x p r e s s i o nw i t h i n
primary tumors. However in samples 6 and 8, metastatic
lesions in the lungs of mice bearing primary tumors
demonstrated variable re-expression of ERa,w h e r e a s
the normal lung tissue did not exhibit expression of
ERa. Interestingly, samples 6 and 8 were derived from
patient biopsies clinically diagnosed as ERa positive.
Previous clinical studies have reported differences in the
expression of ERa between the primary patient tumor
and the metastatic sites [54,55] although the underlying
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unknown. These results reinforce the importance of the
microenvironment within the metastatic niche for influ-
ence on the differentiation state of the metastasized
tumor cells and the expression of clinically relevant
markers. The heterogeneity of the metastatic cells within
the lung and the liver implied plasticity, whether innate
or induced, during the metastatic process. Collectively,
these findings demonstrate the complex integration of
extrinsic and intrinsic factors affecting the behavior and
phenotype of breast cancer cells during the metastatic
process.
T h ep r e s e n ts t u d yd a t ad e m o n s t r a t e san o v e lm o d e l
for the study of human breast cancer breast cancer
metastasis using samples obtained directly from patient
biopsies. The metastatic phenotype demonstrated upon
injection of tumorspheres into the mammary fat pad
permits the study of all steps within the metastatic pro-
cess. In particular, the development of macrometastatic
lesions with organ-specific phenotypic distinctions pro-
vides a superior model for the investigation of organ-
specific effects on metastatic cancer cell survival and
growth. This model accurately recapitulates the meta-
static latency observed clinically, permitting the develop-
ment of therapeutics that target metastatic cells during
dormancy prior to activation. Experimental manipula-
tion of the organ-specific microenvironment could
reveal molecular targets that are clinically accessible and
biologically relevant. Furthermore, this model can be
used to develop improved methods for the detection of
micrometastatic cells and the prediction of metastatic
disease.
Conclusions
Primary breast tumor-initiating cells can be isolated as
tumorspheres under non-adherent, serum free culture
conditions from patient core biopsies independent of
assigned grade or ER/PR/Her2 status. Isolated tumor-
spheres were tumorigenic in NUDE mice and had the
capacity to metastasize from the primary site (i.e. mam-
m a r yf a tp a d )t od i s t a n to r g a n s ,s u c ha st h el i v e r ,l u n g ,
kidney, brain, and femur. Tumor cells at the metastatic
sites exhibited organ-specific phenotypes that demon-
strated plasticity of the metastatic cells dependent upon
the organ microenvironment. This study describes a
reproducible heterotransplant tumor model derived
from patient biopsies that provides a novel method for
the comprehensive study of breast cancer metastasis
that better recapitulates the dormancy, complexity and
heterogeneity within human breast cancer metastases.
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Additional material
Additional file 1: Figure S1. Characterization of cell surface marker
expression of tumorspheres. A. Immunocytochemistry (ICC) of
tumorspheres prepared by formalin fixation and 5 μm paraffin-
embedded sections using pre-conjugated antibodies against CD44-PE,
and CD24-FITC. ICC for ESA-FITC was performed on tumorspheres
prepared by centrifugation onto glass coverslips (cytospins).
Tumorspheres demonstrate a CD44
+/CD24
low-med/ESA
+ cell surface
marker phenotype. B. Isotype matched, pre-conjugated IgG control
antibody mixture (IgG1-PE/IgG2a-FITC) was used as a negative control for
ICC. 200× magnification in all panels.
Additional file 2: Figure S2. MCF-7 and MDA-MB-231 breast tumor
xenografts used as controls for IHC. A-L IHC performed on 5 μm
paraffin-embedded sections of MCF-7 (A-F) and MDA-MB-231 (G-L)
xenografts using rabbit monoclonal E-cadherin antibody (A+G), rabbit
polyclonal b-catenin antibody (B+H), rabbit polyclonal fibronectin
antibody (C+I), rabbit monoclonal Her2/ErbB2 antibody (D+J), rabbit
polyclonal cytokeratin 8 antibody (E+K), and rabbit monoclonal
cytokeratin 14 antibody (F+L). IHC results on MCF-7 and MDA-MB-231
xenograft sections were used as positive and negative controls for the
IHC results on tumors formed after injection of tumorspheres in the
mammary fat pad (Figure 3). All panels 200× magnification.
Additional file 3: Figure S3. Human nuclear antigen (HNA) staining
detects human cells at in the primary tumor and at the metastatic
sites. A.5μm paraffin-embedded sections of MDA-MB-231 breast tumor
xenograft used as a positive control for HNA (mouse anti-human nuclei
monoclonal antibody) staining. B. Tumor sample matched negative
control, with the replacement of the primary antibody with 1× PBS. C.
Kidney isolated from a non-injected NUDE mouse, incubated with HNA
to demonstrate human specificity with the lack of nuclear staining of the
mouse kidney cells. D. Cells stain positive for HNA in 5 μm paraffin-
embedded sections of a tumor removed from the mammary fat pad
after injection of tumorspheres. E-F. HNA staining of 5 μm paraffin-
embedded sections of metastatic lesions in the liver and lung,
respectively confirms the human origin of the lesion, with the majority of
nuclei staining positive. All panels 200× magnification.
Additional file 4: Figure S4. Correlation between metastatic burden
and the time after injection of tumorspheres that mouse organs
were removed. Graphical representation of the percent metastatic
burden, previously calculated as described in Figure 6, for each tissue for
each sample as a function of the time the organs were removed after
initial injection of tumorspheres into the mammary fat pad (Days post-
injection). Values are reported as mean +/- SD.
Additional file 5: Table S1. Summary of heterogeneous marker
expression between primary tumor (mammary fat pad) and
metastatic lesions. Tabular representation of the expression of E-
cadherin, b-catenin, fibronectin, and ERa between samples in the
primary tumor (mammary fat pad), metastatic lesions in the lung and the
liver. Cytoplasmic localization is expressed as ‘cyto’ in the table. ‘Variable’
indicates the variability of staining within metastatic lesions.
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